Health Technology Assessment

Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.

When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.

OHE’s Koonal Shah and Nancy Devlin are co-authors on two new papers focusing on the valuation of the EQ-5D-5L in Ireland.

This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma.

A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2018 conference in Vancouver, 1-5 June.

OHE’s Prof Nancy Devlin has been collaborating on a new approach to creating personal and social EQ-5D-5L value sets, based on a web application.

Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper to the 2017 ICER Membership Policy Summit and 2) a follow up paper based on the discussion at the Summit.

Just published in Social Science & Medicine: a review of stated preferences examining the extent of support for an end of life premium.

A recently published editorial by OHE’s David Mott considers whether quantitative patient preference data has a role to play in HTA decision making.

Pages

Subscribe to RSS - Health Technology Assessment